TITLE:
Analysis of Strategy for Extending Patent Protection of Rucaparib
AUTHORS:
Zhifeng Wang
KEYWORDS:
Patent Portfolio, Patent Analysis, Rucaparib, New Drug Research and Development, Patent Protection
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.9,
August
30,
2023
ABSTRACT: As a knowledge-intensive and promising strategic emerging industry, the biomedical industry has high entry thresholds, large R&D investment, long cycle, high risk and high return. In all technical fields, the biomedical industry has the highest dependence on intellectual property rights, and the protection of pharmaceutical intellectual property rights by domestic and foreign biomedical enterprises also runs through the whole process of drug research and development. Extending the patent protection period of drugs as well as forming and strengthening patent fortresses requires a patent network that surrounds drugs to maximize the value of intellectual property protection, which is also the focus of every pharmaceutical company with patent rights. By analyzing the patent portfolio of Clovis Oncology Company in the United States on Rucaparib and the patent portfolio of other companies or applicants on Rucaparib, we can have a clearer understanding of the strategy of extending the patent protection period of a new drug product.